tirzepatide cvot results Cardiovascular outcomes of semaglutide and for patients with type 2 diabetes in clinical practice 🫀 EASD 2025: Tirzepatide (SURPASS-CVOT)

The theory about the results here is that weight loss might affect brain cells involved in a particular hormonal signaling system (the hypothalamic-pituitary-testicular axis) that is impaired in men with metabolic hypogonadism, the researchers say

Another cohort study of the same TriNetX database found that 193 IIH patients taking tirzepatide had a reduction in BMI of 1.147 mm/kg 2 greater than 193 controls (18)

Compounded Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss: the Direct-to-Consumer Market in Colorado

Lingvay I, Sumithran P, Cohen RV, le Roux CW

These episodes typically resolve when the underlying trigger is addressed

The delayed gastric emptying effect of tirzepatide may also contribute to feelings of fullness and reduced food intake